BACKGROUND: Anticoagulation therapy is followed by analysis of factors used in the CHA2DS2-VASc score and assessing the risk of @entity548 (HAS-BLED). THE AIM OF THE STUDY: The aim of the study was to evaluate in 'real life' risk stratification scores in nonvalvular @entity955 ( @entity955 ). MATERIAL AND METHODS: From 81 consecutive @entity1 who had not yet received anticoagulation, 68 were finally enrolled after exclusion criteria. @entity1 were analyzed related to risk scores: CHADS2 >=  2 (group I) vs. CHADS2 < 2 and CHA2DS2-VASc score >=  2 (group II) and gender. @entity1 at high @entity1031 were treated with @entity1229 , after consideration of the @entity1 's decision. RESULTS: At high risk of @entity1031 complications were 61 @entity1 (90%). In 26 subjects (43%, 15 @entity1 - 57%) indication for anticoagulation was established by CHA2DS2-VASc. When compared to CHADS2 >=  2, these @entity1 were younger (72   10 years vs. 63   10 years, p = 0.0002), less frequently burdened with arterial @entity101 (p = 0.03) and had lower risk in HAS-BLED (1.23   0.65 vs. 0.81   0.49, p = 0.03). Seven @entity1 (10%) did not require anticoagulation (CHA2DS2-VASc = 0). Compared to @entity1 , @entity1 more often had @entity385 (2 vs. 18%, p = 0.03), but less @entity453 (58 vs. 25%, p = 0.005). During 18 months on @entity1229 , @entity548 occurred in 9 @entity1 (13%, 6 @entity1 ). On dual antiplatelet therapy were 11 @entity1 (16%). No @entity1031 complications were recorded. CONCLUSIONS: CHA2DS2-VASc and HAS-BLED schemata easily identify real low and high @entity1031 @entity1 and @entity548 risk. It seems that @entity1 present higher risk of @entity548 , but less frequent use of antiplatelet therapy.

Truly low and high XXXX - impact of risk scores in real life.

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'patient', 'men'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic risk', 'thromboembolic'] @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation', 'AF'] @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease'] @entity1229 :: ('MESH:D014859', 'Chemical') :: ['warfarin'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity1031 :: (MESH:D013923,Disease) :: ['thromboembolic risk']
